Transformative therapies for rare CFTR missense alleles

Kathryn E. Oliver, Sangwoo T. Han, Eric J. Sorscher, Garry R Cutting

Research output: Contribution to journalReview article

Abstract

With over 1900 variants reported in the cystic fibrosis transmembrane conductance regulator (CFTR), enhanced understanding of cystic fibrosis (CF) genotype–phenotype correlation represents an important and expanding area of research. The potentiator Ivacaftor has proven an effective treatment for a subset of individuals carrying missense variants, particularly those that impact CFTR gating. Therapeutic efforts have recently focused on correcting the basic defect resulting from the common F508del variant, as well as many less frequent missense alleles. Modest enhancement of F508del-CFTR function has been achieved by combining Ivacaftor with Lumacaftor, a compound that aids maturational processing of misfolded CFTR. Continued development of in silico and in vitro models will facilitate CFTR variant characterization and drug testing, thereby elucidating heterogeneity in the molecular pathogenesis, phenotype, and modulator responsiveness of CF.

Original languageEnglish (US)
Pages (from-to)76-82
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume34
DOIs
Publication statusPublished - Jun 1 2017

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this